Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.

Hensley, Patrick J; Seiler, Roland; Herr, Harry; Mouw, Kent W; Iyer, Gopa; Dyrskjøt, Lars; Nawroth, Roman; Goebell, Peter; Schmitz-Drager, Bernd; Todenhofer, Tilman; Black, Peter C; Kamat, Ashish M; Williams, Stephen B (2023). Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1. Urologic oncology - seminars and original investigations, 41(7), pp. 307-312. Elsevier 10.1016/j.urolonc.2023.01.001

Text 1-s2.0-S1078143923000017-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (299kB)

The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.

Interest & Impact

Downloads

0 since deposited on 30 Jan 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item